SHL Telemedicine Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Arnon
- Full Time Employees
- 583
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- Ashdar Building Tel Aviv Israel 67891
- IPO Date
- Apr 3, 2023
- CIK
- 0001166834
- Website
- shl-telemedicine.com
- Similar Companies
- Business
- SHL Telemedicine Ltd. develops and markets advanced personal telemedicine solutions and provides medical call center services focused on cardiovascular conditions and chronic diseases to individuals, physicians, hospitals, health insurers, and healthcare providers in Israel, Europe, and internationally. The company offers core products including SmartHeart, an FDA-cleared mobile 12-lead ECG device for heart attack detection; CardioSen’C and Cardio’B, portable 12-lead ECG transmitters; TelePress, a remote blood pressure monitoring device with automatic self-pressurization; central communication modules for transmitting data from devices measuring weight, oxygen saturation via TelePulse Oximeter, breath exhalation via TeleBreather, and glucose levels; and chronic disease management programs for congestive heart failure, COPD, and related conditions leveraging cloud technology, AI, and big data for real-time analysis and intervention. Founded in 1987 and headquartered at 90 Yigal Alon Street in Tel Aviv, Israel, SHL Telemedicine operates 24/7 monitoring centers, with significant presence in Germany and expansion efforts in the United States. In March 2025, the company acquired the remaining 30% stake in Mediton Group, a leading Israeli provider of diagnostics and preventative healthcare services, for approximately USD 8.4 million to capture operational synergies; it also completed a rights offering and capital increase in December 2025 to fund system upgrades in its German subsidiary and boost U.S. sales and marketing.
DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care
SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity
SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test
SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch
SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones
Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post-ACS Patient Care
SHL Telemedicine's SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment
SHL Telemedicine: Invitation to Conference Call Presenting Annual Results 2023
SHL Telemedicine Receives Buy Rating with $11.00 Price Target
Imperial College London TELE-ACS Clinical Trial Results, Using SHL Telemedicine's SmartHeart® Technology, to Be Presented at ACC 24
SHL Telemedicine and BARMER to Highlight Digital Patient Care at BMC Congress 2024
SHL Telemedicine Introduces SmartHeart® Direct-to-Consumer Membership Plan in the US
SHL Telemedicine Establishes US Nationwide Cardiology Network for ECG Interpretations and Telehealth Visits
SHL Telemedicine Announces Advancements in its Direct-to-Consumer Strategy in the US
SHL Telemedicine's SmartHeart® Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials
SHL Announces Half-Year Results 2023 – Strategic Moves to Accelerate Growth
SHL Telemedicine's SmartHeart® Technology to Take Center Stage at Upcoming VPM 2023 Conference
SHL Telemedicine: Half-year results 2023 and Conference Call Scheduled for September 21, 2023